Approved monoclonal antibodies for cancer therapy

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1151-1158

  Boyiadzis, Michael ^a,b   Foon, Kenneth A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Immunotherapy; Monoclonal antibodies; Treatment

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PENTOSTATIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; TIOGUANINE; TOSITUMOMAB I 131; TRASTUZUMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; B CELL LYMPHOMA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER THERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COUGHING; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; FISTULA; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDLINE; MONOTHERAPY; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; PROTEINURIA; PRURITUS; RASH; REVIEW; RIGOR; SINUSOIDAL OBSTRUCTIVE SYNDROME; SOLID TUMOR; SWELLING; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VOMITING; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 48049118634     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1151     Document Type: Review

References (62)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
2. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vivo susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia:further regulation by CD55 and CD59. Blood 2001;98:3383-9
3. Golay J, Zaffaroni L, Vaccari T, et al. Biologic responses of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro:CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8
4. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B cell malignancies. J Immunother 2001;24(3):263-71
5. Cartron G, Dacheaux L, Salles G, et al. Therapeutic activity of humanized anit-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FeYRIIIa gene. Blood 2002;99:754-8
6. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7
7. Wenk WK, Levy R. Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma [abstract]. Blood 2002;100
8. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways:implications in chemo immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26(25):3629-36
9. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B cell chronic lymphocytic leukemia:evidence of caspase activation and apoptosis induction. Blood 2002;99(3):1038-43
10. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab:ongoing and future clinical development. Semin Oncol 2002;29:105-12
11. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
12. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8:results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15(10):3266-74
13. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
14. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule. Blood 2004;103(12):4416-23
15. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-DC20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10(6):655-61
16. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20(20):4261-7
17. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation. Blood 2001;97(l):101-6
18. Witzig TE, Kukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma:a Phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23(6):1103-8
19. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
20. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up. J Clin Oncol 2004;22(23):4711-6
21. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with CHOP alone:results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005;106(12):3725-32
22. Forstpointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle-cell lymphomas-results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004;104:3064-71
23. Herold M, Pasold R, Srock S, et al. Results of a randomized open label phase-3 study comparing rituximab plus mixantrone, chlorambucil, prednisone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle-cell lymphoma [abstract]. Blood 2004;104:169a
24. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002;346(4):235-42
25. Feugier P, Hoof AV, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma:a study by the Groupe d-Etude des Lymphomes de I'Adulte. J Clin Oncol 2005;23(18):4117-26
26. Haberman TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. J Clin Oncol 2006;24(19):3121-7
27. Preundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B cell lymphoma:a randomized controlled trial by the Mab Thera International Trial (MInT) Group. Lancet Oncol 2006;7(5):379-91
28. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079-88
29. Tarn CS, O'Brien S, Wierda W, et al. Seventy percent of complete responders remain in continuous remission:five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab(FCR) as initial therapy of CLL [abstract]. J Clin Oncol 2007;25:18S
30. Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B cell chronic lymphocytic leukemia:results from Cancer and Leukemia Group B. Blood 2003;101(1):6-14
31. Tarhini AA, Land S, Meisner D, et al. Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL) [abstract]. Blood 2006; 108
32. Kay NE, Geyer SM, Call TC, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109(2):405-11
33. Leonard JP. Targeting CD20 in follicular NHL:novel anti-CD20 therapies antibody engineering, and the uses of radioimmunoconjugates. Hematology Am Soc Hematol Educ Program 2005;335-9
34. Witzig TE, Gordon LI, Cabaniallas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63
35. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9
36. Leonard JP, Coleman M, Kostakoblu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23(24);5696-704
37. Zinzani PL, Pulsoni A, Balocco M, et al. A Phase II trial of FM (oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for previously untreated follicular lymphoma (FL) patients [abstract]. Blood 2006; 108:11
38. Press OW, Unger JM, Brazeil RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma:five-year follow up of Southwest Oncology Group protocol S9911- J Clin Oncol 2006;24(25):4143-9
39. Shipley DL, Spigel DR, Carrell DL, et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibrtumomab tiuxetan as first-line treatment for patients with follocular lymphoma:a Minnie Pearl Cancer Research Network Phase II trial [abstract]. J Clin Oncol 2004;22(14S)
40. Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of I131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol 2004;22(14S)
41. Jankowitz RC, Demonaco NA, Foon KA, et al. Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan(IT) as first-line treatment for follicular lymphoma (FL) [abstract]. J Clin Oncol 2007;25(18S)
42. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine I311 tositumomab for relapsed or refractory B cell non-Hodgkin lymphoma:updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66
43. Kaminski MS, Zelenetz AD, Press UW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28
44. Kaminski MJ, Tuck M, Ester J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphomas. N Engl J Med 2005;352:441-9
45. Keating MJ, Flinn J, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine:results of a large international study. Blood 2002;99:3554-61
46. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1h) as first-line treatment for patients with B cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73
47. Hillman P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23
48. Keating MJ, Cazin B, Courte S, et al. Campath-1H treatment of T cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13
49. Lundin J, Hagber H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-72
50. Fenton C, Perry CM. Gemtuzumab ozogamicin:a review of its use in acute myeloid leukemia. Drugs 2005;65:2405-27
51. Pagano L. Fianchi L, Caira M, et al. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 2007;26:3679-90
52. McKoy JM, Angellota C, Giles FJ, et al. Gemtuzumab ozogamicin-associated sinsusoidal obstructive syndrome (sos):an overview from the research on adverse drug events and reports (radar) project. Leuk Res 2007;31:599-604
53. Wadleigh M, Richardson PG, DeAngelo DJ, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-82
54. Cobleigh MA, Vogel CL, Tripathey D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-348
55. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
56. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
57. Sandler A, Gray R, Schiller JH, et al. Paclitaxel-Carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEJM 2006;355:2542-50
58. Miller K, Wang M, Davidson NE, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
59. Cunnigham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
60. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (NSCLC) [abstract 2582]. Proc Am Soc Clin Oncol 2003;22
61. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
62. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-7